Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)‘s stock had its “hold” rating reiterated by analysts at Needham & Company LLC in a research note issued on Sunday.

A number of other equities research analysts also recently weighed in on the company. Stifel Nicolaus reiterated a “buy” rating and issued a $13.00 price objective on shares of Tetraphase Pharmaceuticals in a report on Tuesday, September 12th. ValuEngine downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Zacks Investment Research downgraded Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 30th. Piper Jaffray Companies began coverage on Tetraphase Pharmaceuticals in a report on Monday, August 28th. They issued an “overweight” rating and a $14.00 price objective for the company. Finally, BidaskClub upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 22nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $10.88.

Tetraphase Pharmaceuticals (TTPH) opened at 6.94 on Friday. The stock’s market cap is $354.31 million. Tetraphase Pharmaceuticals has a 52 week low of $3.11 and a 52 week high of $9.93. The company has a 50-day moving average of $6.28 and a 200-day moving average of $7.27.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.07). The business had revenue of $1.59 million during the quarter, compared to analyst estimates of $1.54 million. Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. Tetraphase Pharmaceuticals’s revenue for the quarter was up 28.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.47) EPS. On average, analysts predict that Tetraphase Pharmaceuticals will post ($2.54) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/17/tetraphase-pharmaceuticals-inc-ttph-stock-rating-reaffirmed-by-needham-company-llc.html.

In other news, insider Jacques Dumas sold 17,500 shares of the company’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $6.00, for a total transaction of $105,000.00. Following the completion of the transaction, the insider now directly owns 17,500 shares of the company’s stock, valued at $105,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 5.50% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of TTPH. AXA acquired a new position in Tetraphase Pharmaceuticals during the second quarter valued at approximately $132,000. Teza Capital Management LLC boosted its position in Tetraphase Pharmaceuticals by 8.9% during the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 1,281 shares during the last quarter. Citadel Advisors LLC boosted its position in Tetraphase Pharmaceuticals by 18.6% during the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock valued at $146,000 after purchasing an additional 2,496 shares during the last quarter. Virtu KCG Holdings LLC acquired a new position in Tetraphase Pharmaceuticals during the second quarter valued at approximately $147,000. Finally, Voya Investment Management LLC boosted its position in Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 3,104 shares during the last quarter. 41.73% of the stock is owned by hedge funds and other institutional investors.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.